http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국인 류마티스 관절염 환자에서 질병 중증도 표지자로서의 HLA-DR4 유용성
임미경 ( M. K. Lim ),이창근 ( C. K. Lee ),최승원 ( S. W. Choi ),주용선 ( Y. S. Ju ),주유숙 ( Y. S. Cho ),김성문 ( S. M. Kim ),신명진 ( M. J. Shin ),오흥범 ( H. B. Oh ),유빈 ( B. Yoo ),문희범 ( H. B. Moon ) 대한류마티스학회 2001 대한류마티스학회지 Vol.8 No.1
Objective: To investigate HLA-DR4, its subtype and shared epitope as a severity marker in Korean patients with rheumatoid arthritis. Methods: One hundred thirty-six RA patients were typed for HLA DR4 and HLA-DRB1 alleles by the polymerase chain reaction-sequence specific probe method. The patients were retrospectively evaluated for extra-articular features, presence of remission, and joint failure. Bony erosion score was assessed by Sharp`s method with modification. Results: Patients with HLA-DR4 had significantly higher prevalence of extra-articular features compared to those without the allele. However, there was no association of HLA-DR4, HLA-DRB1*0405 and shared epitope with rate of remission, joint failure, and bony erosion score. Eighty-two percent of patients were rheumatoid factor positive. With seropositive patients only, the results were the same as those above. Conclusion: HLA-DR4, HLA-DRB1*0405 and shared epitope are not a severity marker in Korean patients with RA in terms of radiological score, rate of joint failure, and rate of clinical remission. Data from this study do not support the clinical use of HLA-DR4 typing as a prognostic marker in Korean patients with RA.
직업성천식 감시체계에 등록된 우리나라의 직업성천식 실태
강성규(Seong Kyu Kang),지영구(Young Koo Jee),남동호(Dong Ho Nahm),민경업(Kyung Up Min),박중원(Jung Won Park),박해심(Hae Sim Park),손춘희(Seong Kyu Kang),조상헌(Sang Heon Cho),최인선(In Seon Choi),최승원(Seung Won Choi),홍천수(Chein S 대한천식알레르기학회 2000 천식 및 알레르기 Vol.20 No.6
N/A Background: Since asthma caused by toluene diisocyanate (TDI) was reported at a polyurethane paint factory, occupational asthma there has been increasing concern of in both allergic and occupational health. However, the statistics of occupational asthma did not reflected its seriousness because of many barriers related to legal reporting. Since fild a voluntary report from a clinician sent directly to a surveillance center would allow more cases to be filed without any disadvantage to workers and employers, we developed a surveillance system to facilitate the reporting of occupational asthma. Methods : Allergists and pulmonary physicians were asked to report to the Occupational Asthma Surveillance Center(OASC) using a mail, fax or e-mail if work-related asthma was diagnosed. A claimed case for occupational asthma to the Occupational Health Research Institute was also included. The OASC contacted the workers by phone and investigated the workplace if necessary. The reported cases from October, 1998 to November, 1999 were analysed. Results: Thirty-three cases were reported with 29 males and four females. The mean age was 44 and the mean latency period was 5.4 years. Twenty-one cases were caused by a known allergen inducer with objective evidence. The causative agents included TDI in 45.5 %(15), followed by reactive dye in 24.2 %(8). welding fume(2), formaldehyde(1), paint (1), toluene(1). styrene(1), exhaustive gas(1), and wood dust(1). Among these cases, there were seven dyers, four painters, three machine operators and furniture finishers, two assemblers and tanneries. Eighteen cases had claimed Workers Compensation Insurance and all were accepted. The reasons for not claiming Insurance included ignorance(28.5%), feat of job dismissal (23.8%), other reasons (9.5 %), agreement with the employer(14.3%) and employer hirnself(9.5 %) Conclusion : The OASC by allergists was an effective system to find unreported cases and to provide a prevention strategy of occupational asthma. Occupational asthma was mostly caused by TDI and reactive dye. Painters and dyers were the most common occupations causing occupational asthma. Only half of occupational asthma patients claimed compensation because of workers ignorance and fear of being fired. (J Asthma Allergy Clin Immunol 20: 906-15, 2000)